{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:19:29Z","timestamp":1790324369819,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,10,19]],"date-time":"2012-10-19T00:00:00Z","timestamp":1350604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0"}],"content-domain":{"domain":["intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1017\/s1041610212001627","type":"journal-article","created":{"date-parts":[[2012,10,19]],"date-time":"2012-10-19T13:42:39Z","timestamp":1350654159000},"page":"185-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review"],"prefix":"10.1016","volume":"25","author":[{"given":"Dallas P.","family":"Seitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Brisbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Rines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Le Clair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Conn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1017\/S1041610212001627_bb0010","unstructured":"Alexopoulos G. S. , JesteD. V., ChungH., CarpenterD., RossR. and DochertyJ. P. (2005). The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgraduate Medicine, Spec No, 6."},{"key":"10.1017\/S1041610212001627_bb0015","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.4088\/JCP.09r05786blu","article-title":"Serontonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and reconsideration of mechanisms","volume":"71","author":"Andrade","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrn1926","article-title":"Neuroleptic drugs in dementia: benefits and harm","volume":"7","author":"Ballard","year":"2006","journal-title":"Nature Reviews Neuroscience"},{"key":"10.1017\/S1041610212001627_bb0025","doi-asserted-by":"crossref","unstructured":"Ballard C. and WaiteJ. (2006). The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews (Online), (1), CD003476.","DOI":"10.1002\/14651858.CD003476.pub2"},{"key":"10.1017\/S1041610212001627_bb0030","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4088\/JCP.v65n0120","article-title":"A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome","volume":"65","author":"Ballard","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0035","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","article-title":"Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial","volume":"330","author":"Ballard","year":"2005","journal-title":"British Medical Journal"},{"key":"10.1017\/S1041610212001627_bb0040","doi-asserted-by":"crossref","first-page":"0587","DOI":"10.1371\/journal.pmed.0050076","article-title":"A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial)","volume":"5","author":"Ballard","year":"2008","journal-title":"PLoS Medicine"},{"key":"10.1017\/S1041610212001627_bb0045","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/YCO.0b013e32833111f9","article-title":"Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions","volume":"22","author":"Ballard","year":"2009","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrneurol.2009.39","article-title":"Management of agitation and aggression associated with Alzheimer disease","volume":"5","author":"Ballard","year":"2009","journal-title":"Nature Reviews Neurology"},{"key":"10.1017\/S1041610212001627_bb0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1474-4422(08)70295-3","article-title":"The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial","volume":"8","author":"Ballard","year":"2009","journal-title":"The Lancet Neurology"},{"key":"10.1017\/S1041610212001627_bb0060","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1017\/S1041610211000743","article-title":"Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind study","volume":"23","author":"Barak","year":"2011","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610212001627_bb0065","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1176\/ajp.139.9.1170","article-title":"Efficacy of antipsychotic medications in behaviorally disturbed dementia patients","volume":"139","author":"Barnes","year":"1982","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0070","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.psc.2005.09.004","article-title":"Evidence-based interventions for nursing home residents with dementia-related behavioral symptoms","volume":"28","author":"Bharani","year":"2005","journal-title":"Psychiatric Clinics of North America"},{"key":"10.1017\/S1041610212001627_bb0075","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.48.5_Suppl_6.17S","article-title":"Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease","volume":"48","author":"Borson","year":"1997","journal-title":"Neurology"},{"key":"10.1017\/S1041610212001627_bb0080","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4088\/JCP.v64n0205","article-title":"A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia","volume":"64","author":"Brodaty","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0085","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2105\/AJPH.83.3.331","article-title":"Mental health service use by the elderly in nursing homes","volume":"83","author":"Burns","year":"1993","journal-title":"American Journal of Public Health"},{"key":"10.1017\/S1041610212001627_bb0090","series-title":"National Guidelines for Seniors\u2019 Mental Health: The Assessment and Treatment of Mental Health Issues in Long Term Care Homes","author":"Canadian Coalition for Seniors\u2019 Mental Health","year":"2006"},{"key":"10.1017\/S1041610212001627_bb0095","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00019442-199622430-00011","article-title":"Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease","volume":"4","author":"Cantillon","year":"1996","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0100","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jamda.2008.04.009","article-title":"Nursing home physicians\u2019 knowledge of and attitudes toward nonpharmacological interventions for treatment of behavioral disturbances associated with dementia","volume":"9","author":"Cohen-Mansfield","year":"2008","journal-title":"Journal of the American Medical Directors Association"},{"key":"10.1017\/S1041610212001627_bb0105","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/gps.1171","article-title":"Assessment of agitation in elderly patients with dementia: correlations between informant rating and direct observation","volume":"19","author":"Cohen-Mansfield","year":"2004","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.wad.0000155066.39184.61","article-title":"Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia","volume":"19","author":"Cohen-Mansfield","year":"2005","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1017\/S1041610212001627_bb0115","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.159.15.1733","article-title":"Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home","volume":"159","author":"Cohen-Mansfield","year":"1999","journal-title":"Archives of Internal Medicine"},{"key":"10.1017\/S1041610212001627_bb0120","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jamda.2011.07.006","article-title":"What are the barriers to performing nonpharmacological interventions for behavioral symptoms in the nursing home?","volume":"13","author":"Cohen-Mansfield","year":"2012","journal-title":"Journal of the American Medical Directors Association"},{"key":"10.1017\/S1041610212001627_bb0125","series-title":"Mental health issues in long-term care facilities","article-title":"Practical Psychiatry in the Nursing Home: A Handbook for Staff.","author":"Conn","year":"1992"},{"key":"10.1017\/S1041610212001627_bb0130","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/YCO.0b013e32833efe56","article-title":"Advances in the treatment of psychiatric disorders in long-term care homes","volume":"23","author":"Conn","year":"2010","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0135","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/(SICI)1099-1166(199610)11:10<901::AID-GPS409>3.0.CO;2-7","article-title":"Carbamazepine use in aggressive behaviour associated with senile dementia","volume":"11","author":"Cooney","year":"1996","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0140","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1212\/WNL.53.5.946","article-title":"). A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia","volume":"53","author":"De Deyn","year":"1999","journal-title":"Neurology"},{"key":"10.1017\/S1041610212001627_bb0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/gps.1032","article-title":"Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease","volume":"19","author":"De Deyn","year":"2004","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0150","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archinte.164.3.327","article-title":"Paroxetine-induced hyponatremia in older adults","volume":"164","author":"Fabian","year":"2004","journal-title":"Archives of Internal Medicine"},{"key":"10.1017\/S1041610212001627_bb0155","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/bmj.326.7389.580","article-title":"Quality of care for elderly residents in nursing homes and elderly people living at home: controlled observational study","volume":"326","author":"Fahey","year":"2003","journal-title":"BMJ"},{"key":"10.1017\/S1041610212001627_bb0160","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4088\/JCP.v64n0617","article-title":"A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities","volume":"64","author":"Fontaine","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl.","key":"10.1017\/S1041610212001627_bb0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0167-4943(01)00135-2","article-title":"Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia","volume":"33","author":"Gaber","year":"2001","journal-title":"Archives of Gerontology and Geriatrics"},{"key":"10.1017\/S1041610212001627_bb0170","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1017\/S1041610209991505","article-title":"Management of behavioral problems in Alzheimer's disease","volume":"22","author":"Gauthier","year":"2010","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610212001627_bb0175","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/JGP.0b013e318187de18","article-title":"Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease","volume":"17","author":"Gehrman","year":"2009","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0180","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/bmj.38330.470486.8F","article-title":"Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study","volume":"330","author":"Gill","year":"2005","journal-title":"British Medical Journal"},{"key":"10.1017\/S1041610212001627_bb0185","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","article-title":"Antipsychotic drug use and mortality in older adults with dementia","volume":"146","author":"Gill","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"10.1017\/S1041610212001627_bb0190","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1532-5415.2004.52451.x","article-title":"Behavioral symptoms in residential care\/assisted living facilities: prevalence, risk factors, and medication management","volume":"52","author":"Gruber-Baldini","year":"2004","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1017\/S1041610212001627_bb0195","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S1041610205001535","article-title":"Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial","volume":"17","author":"Hall","year":"2005","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610212001627_bb0200","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00023210-200519020-00001","article-title":"Do atypical antipsychotics cause stroke?","volume":"19","author":"Herrmann","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1017\/S1041610212001627_bb0205","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/070674370705201004","article-title":"Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease","volume":"52","author":"Herrmann","year":"2007","journal-title":"Canadian Journal of Psychiatry (Revue canadienne de psychiatrie)"},{"key":"10.1017\/S1041610212001627_bb0210","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1176\/appi.ajp.161.6.1113","article-title":"Atypical antipsychotics and risk of cerebrovascular accidents","volume":"161","author":"Herrmann","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0215","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jalz.2007.07.007","article-title":"Clinical practice guidelines for severe Alzheimer's disease","volume":"3","author":"Herrmann","year":"2007","journal-title":"Alzheimer's and Dementia"},{"key":"10.1017\/S1041610212001627_bb0220","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1532-5415.2005.53403.x","article-title":"Aytypical antipsychotic medications and risk of falls in residents of aged care facilities","volume":"53","author":"Hien Le","year":"2005","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1017\/S1041610212001627_bb0225","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1017\/S1041610212001627_bb0230","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/gps.1667","article-title":"Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study","volume":"22","author":"Holmes","year":"2007","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0235","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa066583","article-title":"Donepezil for the treatment of agitation in Alzheimer's disease","volume":"357","author":"Howard","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1017\/S1041610212001627_bb0240","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4088\/JCP.v68n0314","article-title":"Antiaggressive effect of cyproterone versus haloperidol in Alzheimer's disease: a randomized double-blind pilot study","volume":"68","author":"Huertas","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0245","first-page":"E411","article-title":"Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes","volume":"183","author":"Huybrechts","year":"2011","journal-title":"Canadian Medical Association Journal"},{"key":"10.1017\/S1041610212001627_bb0250","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jamda.2009.10.001","article-title":"Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia","volume":"11","author":"Jalbert","year":"2010","journal-title":"Journal of the American Medical Directors Association"},{"key":"10.1017\/S1041610212001627_bb0255","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1176\/appi.ajp.2007.06101710","article-title":"Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications","volume":"164","author":"Kales","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0260","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archgenpsychiatry.2010.200","article-title":"Trends in antipsychotic use in dementia 1999\u20132007","volume":"68","author":"Kales","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0265","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v60n0207","article-title":"Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group","volume":"60","author":"Katz","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0270","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00002512-200219040-00002","article-title":"Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience","volume":"19","author":"Kindermann","year":"2002","journal-title":"Drugs and Aging"},{"key":"10.1017\/S1041610212001627_bb0275","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1017\/S1041610207006540","article-title":"Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review","volume":"20","author":"Konavalov","year":"2007","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610212001627_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.745","article-title":"Pharmacological management of behavioral and psychological disturbance in dementia","volume":"21","author":"Kozman","year":"2006","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1017\/S1041610212001627_bb0285","first-page":"339","article-title":"Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia. Results from a short-term, randomized, double-blind trial","volume":"7","author":"Kyomen","year":"1999","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0290","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4088\/JCP.v59n1010","article-title":"Efficacy and safety of neuroleptics in behavioral disorders associated with dementia","volume":"59","author":"Lanctot","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0295","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/ageing\/afr032","article-title":"Associated factors with antipsychotic use in assisted living facilities: a cross-sectional study in 4367 residents","volume":"40","author":"Larrayadieu","year":"2011","journal-title":"Age and Ageing"},{"key":"10.1017\/S1041610212001627_bb0300","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1017\/S1041610212001627_bb0305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1037\/0033-3204.33.1.19","article-title":"Psychological consultation to nursing homes: description of a six-year practice","volume":"33","author":"Meeks","year":"1996","journal-title":"Psychotherapy"},{"key":"10.1017\/S1041610212001627_bb0310","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.JGP.0000194643.63245.8c","article-title":"Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial","volume":"14","author":"Mintzer","year":"2006","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0315","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","article-title":"Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses","volume":"15","author":"Mintzer","year":"2007","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0320","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"The Prisma Group","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1017\/S1041610212001627_bb0325","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1017\/S1041610209008916","article-title":"Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia","volume":"21","author":"Nijk","year":"2009","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610212001627_bb0330","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00019442-200111000-00008","article-title":"A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease","volume":"9","author":"Olin","year":"2001","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0335","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.wad.0000155067.16313.5e","article-title":"Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study","volume":"19","author":"Peskind","year":"2005","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1017\/S1041610212001627_bb0340","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1017\/S1041610204000079","article-title":"Behavioral symptoms and the administration of psychotropic drugs to aged patients with dementia in nursing homes and in acute geriatric wards","volume":"16","author":"Pitkala","year":"2004","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610212001627_bb0345","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","article-title":"Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients","volume":"159","author":"Pollock","year":"2002","journal-title":"The American Journal of Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0350","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JGP.0b013e3180cc1ff5","article-title":"A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia","volume":"15","author":"Pollock","year":"2007","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0355","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00019442-200102000-00009","article-title":"Placebo-controlled study of divalproex sodium for agitation in dementia","volume":"9","author":"Porsteinsson","year":"2001","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0360","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jamda.2008.06.006","article-title":"A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia","volume":"10","author":"Rappaport","year":"2009","journal-title":"Journal of the American Medical Directors Association"},{"key":"10.1017\/S1041610212001627_bb0365","first-page":"320","article-title":"Psychiatric consultation in the nursing home: a survey of six states","volume":"6","author":"Reichman","year":"1998","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0370","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/archinte.167.7.676","article-title":"Variation in nursing home antipsychotic prescribing rates","volume":"167","author":"Rochon","year":"2007","journal-title":"Archives of Internal Medicine"},{"key":"10.1017\/S1041610212001627_bb0375","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archinte.168.10.1090","article-title":"Antipsychotic therapy and short-term serious events in older adults with dementia","volume":"168","author":"Rochon","year":"2008","journal-title":"Archives of Internal Medicine"},{"key":"10.1017\/S1041610212001627_bb0380","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1532-5415.2004.52470.x","article-title":"Effect of antipsychotic withdrawal on behavior and sleep\/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study the bergen district nursing home study","volume":"52","author":"Ruths","year":"2004","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1017\/S1041610212001627_bb0385","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/gps.1998","article-title":"Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study \u2013 the Bergen District Nursing Home Study (BEDNURS)","volume":"23","author":"Ruths","year":"2008","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0390","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/1533317507312957","article-title":"Alzheimer's and non-Alzheimer's dementia: a critical review of pharmacological and nonpharmacological strategies","volume":"23","author":"Saddichha","year":"2008","journal-title":"American Journal of Alzheimer's Disease and Other Dementias"},{"key":"10.1017\/S1041610212001627_bb0395","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"Journal of the American Medical Association"},{"key":"10.1017\/S1041610212001627_bb0400","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1532-5415.1990.tb02407.x","article-title":"A metaanalysis of controlled trials of neuroleptic treatment in dementia","volume":"38","author":"Schneider","year":"1990","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1017\/S1041610212001627_bb0405","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","article-title":"Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials","volume":"14","author":"Schneider","year":"2006","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0410","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease","volume":"355","author":"Schneider","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1017\/S1041610212001627_bb0415","series-title":"Cholinesterase inhibitor use in U.S. nursing homes: results from the National Nursing Home Survey","article-title":"American Association of Geriatric Psychiatry Annual Meeting","author":"Seitz","year":"2009"},{"key":"10.1017\/S1041610212001627_bb0420","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1017\/S1041610210000608","article-title":"Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review","volume":"22","author":"Seitz","year":"2010","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610212001627_bb0425","doi-asserted-by":"crossref","unstructured":"Seitz D. , AdenuriN., GillS. S., GruneirA., HerrmannN. and RochonP. A. (2011). Antidepressants for psychosis and agitation in dementia. Cochrane Database of Systematic Reviews, February 16, CD008191.","DOI":"10.1002\/14651858.CD008191.pub2"},{"key":"10.1017\/S1041610212001627_bb0430","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jamda.2011.12.059","article-title":"Efficacy and feasibility of non-pharmacological interventions for neuropsychiatric symptoms of dementia in long-term care: a systematic review","volume":"13","author":"Seitz","year":"2012","journal-title":"Journal of the American Medical Directors Association"},{"key":"10.1017\/S1041610212001627_bb0435","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/gps.1749","article-title":"The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes","volume":"22","author":"Selbaek","year":"2007","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0440","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/JGP.0b013e318167ae76","article-title":"The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes \u2013 a 12-month follow-up study","volume":"16","author":"Selbaek","year":"2008","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0445","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.293.5.596","article-title":"Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence","volume":"293","author":"Sink","year":"2005","journal-title":"Journal of the American Medical Association"},{"key":"10.1017\/S1041610212001627_bb0450","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1046\/j.1532-5415.2003.51417.x","article-title":"). Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature","volume":"51","author":"Snowden","year":"2003","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1017\/S1041610212001627_bb0455","doi-asserted-by":"crossref","unstructured":"Snowdon J. , GalanosD. and VaswaniD. (2011). Patterns of psychotropic medication use in nursing homes: surveys in Sydney, allowing comparisons over time and between countries. International Psychogeriatrics.","DOI":"10.1017\/S1041610211000445"},{"key":"10.1017\/S1041610212001627_bb0460","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000199236","article-title":"Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia","volume":"27","author":"Sommer","year":"2009","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1017\/S1041610212001627_bb0465","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial","volume":"57","author":"Street","year":"2000","journal-title":"Archives of General Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0470","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JGP.0b013e318165db77","article-title":"A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease","volume":"16","author":"Streim","year":"2008","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0475","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1176\/appi.ajp.2008.07111779","article-title":"Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial","volume":"165","author":"Sultzer","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0480","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4065\/76.5.540","article-title":"Assessment and management of behavioral disturbances in nursing home patients with dementia","volume":"76","author":"Sutor","year":"2001","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1017\/S1041610212001627_bb0485","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-200730020-00006","article-title":"Psychotropic medications and the risk of fracture: a meta-analysis","volume":"30","author":"Takkouche","year":"2007","journal-title":"Drug Safety"},{"key":"10.1017\/S1041610212001627_bb0490","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/ajp.155.1.54","article-title":"). Efficacy and tolerability of carbamazepine for agitation and aggression in dementia","volume":"155","author":"Tariot","year":"1998","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0495","first-page":"1590","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting","volume":"49","author":"Tariot","year":"2001","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1017\/S1041610212001627_bb0500","first-page":"942","article-title":"Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial","volume":"13","author":"Tariot","year":"2005","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0505","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.JGP.0000196628.12010.35","article-title":"Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial","volume":"14","author":"Tariot","year":"2006","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0510","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease","volume":"68","author":"Tariot","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0515","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/JCP.0b013e3181dca10a","article-title":"Risk of ischemic stroke associated with antidepressant drug use in elderly persons","volume":"30","author":"Trifiro","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1017\/S1041610212001627_bb0520","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy","volume":"358","author":"Turner","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1017\/S1041610212001627_bb0525","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1041610202008396","article-title":"A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia","volume":"14","author":"Van Reekum","year":"2002","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610212001627_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000089136","article-title":"Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial","volume":"21","author":"Verhey","year":"2006","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1017\/S1041610212001627_bb0535","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00198-005-0065-y","article-title":"Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture","volume":"17","author":"Vestergaard","year":"2006","journal-title":"Osteoporosis International"},{"key":"10.1017\/S1041610212001627_bb0540","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1176\/appi.ajp.2011.08121844","article-title":"Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD","volume":"168","author":"Vigen","year":"2011","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0545","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa052827","article-title":"Risk of death in elderly users of conventional vs. atypical antipsychotic medications","volume":"353","author":"Wang","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1017\/S1041610212001627_bb0550","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/JGP.0b013e3181ab8c61","article-title":"Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression","volume":"17","author":"Wang","year":"2009","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0555","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1176\/appi.ajp.2010.10071064","article-title":"Association of cerebrovascular events with antidepressant use: a case-crossover study","volume":"168","author":"Wu","year":"2011","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610212001627_bb0560","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/156720507779939805","article-title":"Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study","volume":"4","author":"Zhong","year":"2007","journal-title":"Current Alzheimer Research"},{"key":"10.1017\/S1041610212001627_bb0565","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/0891988706292762","article-title":"Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients","volume":"20","author":"Zuidema","year":"2007","journal-title":"Journal of Geriatric Psychiatry and Neurology"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224012778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224012778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1041610212001627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T17:49:11Z","timestamp":1744393751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610224012778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1041610224012778"],"URL":"https:\/\/doi.org\/10.1017\/s1041610212001627","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1017\/S1041610212001627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Copyright \u00a9 International Psychogeriatric Association 2012. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}